Novartis dis-invests influenza vaccine business to CSL for 275 Million USD.

Novartis to dis-invest its influenza vaccines business to CSL ltd for USD 275 million.As this transaction requires regulatory approval,it is expected to close in second half of 2015 .Novartis remains committed to influenza business during the transaction period to closing which also includes honoring agreements with customers ,R&D for influenza vaccines and product launches.
          Earlier , in April 22, 2014 ,Novartis reached a definitive agreement with GSK(Glaxosmithkline) to exchange certain assets , building global leadership in key segments and focusing Novartis portfolio.
 And Novartis announced a definitive agreement with ELI Lilly and Company to divest its Animal health division further focusing its portfolio on leading business of innovative pharmaceuticals , eye care and generics. 

CTI BIOPHARMA, acquires world wide rights to Tosedostat

CTI Biopharma has acquired world wide rights to TOSEDOSTAT through concurrent transactions with Vernalis R&D Ltd and Chroma Therapeutics.Under terms of assets purchase agreement with Chroma Therapeutics , CTI Biopharma acquired Chroma rights,titlle , and interest in TOSEDOSTAT  in exchng for USD 21.3 million in shares to  Chroma Therapeutics.Also CTI Biopharma entered in to license agreement with Vernalis R&D for world wide rights to use IPR(intellectual property rights) and certain patents to develop , market and commercialize TOSEDOSTAT.